Brian Wahlig

Brian Wahlig

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in Journal of Pediatric Orthopaedics
Verified
Journal Article
Closed access
MSMikaela H. Sullivan
Mikaela H. Sullivan
BWBrian Wahlig
Brian Wahlig
SBSamuel E. Broida
Samuel E. Broida
ALA. Noelle Larson
A. Noelle Larson
WSWilliam J. Shaughnessy
William J. Shaughnessy
TMTodd A. Milbrandt
Todd A. Milbrandt
Background: Treatment of supracondylar humerus (SCH) fractures within 18 hours of presentation is a tracked quality metric for ranking of pediatric hospitals. This is in contrast with literature that shows time to treatment does not impact outcomes in SCH fractures. We aim to determine whether an 18-hour cutoff for pediatric supracondylar humerus fracture treatment is clinically significant by comparing the complication risks ofpatients on either side of this timepoint. Our hypothesis is that there will be no statistically significant differences based on time to treatment. Methods: A retrospective review of clinical outcomes was performed for 472 pediatric patients who underwent surgical management of isolated supracondylar humerus fractures between 1997 and 2022 at a single level I pediatric trauma hospital. The cohort was split based on time to surgery (within or ≥18 h from Emergency Department admission). Results: Surgical treatment occurred within 18 hours of arrival in 435 (92.2%) patients and after 18 hours in 37 (7.8%) patients. Mean age was 5.6±2.2 years and 51.5% of patients were female. Gartland fracture classification was type II [n=152 (32.3%)], type III [n=284 (60.3%)], type IV [n=13 (2.8%)], or flexion-type [n=18 (3.8%)]. There were no differences in demographic characteristics or fracture classification between cohorts. Fractures in the ≥18-hour cohort were treated more commonly with 2 pins (62.2% vs. 38.5%, P=0.04). There were no statistically significant differences in open versus closed reduction, utilization of medial pins, or postoperative immobilization between cohorts. We were unable to detect any differences in postoperative complications, including non-union, delayed union, stiffness, malunion, loss of reduction, iatrogenic nerve injury, or infection. This remained true when type II fractures were excluded. Conclusions: Using an arbitrary time cutoff of <18 hours does not influence clinical outcomes in the surgical treatment of SCH fractures. This held true when type II fractures were excluded. For this reason, we recommend modification to the USNWR guidelines to decrease emphasis on time-to-treatment of SCH fractures. Level of Evidence: Level III

25 April 2020 in Virology
Verified
Journal Article
Closed access
TRTawana M. Robinson
Tawana M. Robinson
MHMichelle L. Ho
Michelle L. Ho
BWBrian Wahlig
Brian Wahlig
VGVeronica Gough
Veronica Gough
ABAnton Banta
Anton Banta
JSJunghae Suh
Junghae Suh

19 October 2021 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
PDF file
BWBrian Wahlig
Brian Wahlig
KPKiley Poppino
Kiley Poppino
CJChan‐Hee Jo
Chan‐Hee Jo
KRKarl Rathjen
Karl Rathjen

24 February 2024 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
BWBrian Wahlig
Brian Wahlig
MSMatthew B. Shirley
Matthew B. Shirley
MHMatthew L. Hadley
Matthew L. Hadley
PTPrabin Thapa
Prabin Thapa
AKAaron J. Krych
Aaron J. Krych
RTRobert T. Trousdale
Robert T. Trousdale

13 April 2023 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
BWBrian Wahlig
Brian Wahlig
SBSamuel E. Broida
Samuel E. Broida
PRPeter S. Rose
Peter S. Rose
SRSteven I. Mbbs Robinson
Steven I. Mbbs Robinson
BSBrittany L. Siontis
Brittany L. Siontis
MHMatthew T. Houdek
Matthew T. Houdek
Background: Extraskeletal Ewing sarcoma are rare tumors within the Ewing sarcoma family. Initial staging studies for extraskeletal Ewing sarcoma historically have included imaging and bone marrow aspiration and biopsy (BMAB). However, recent studies on Ewing sarcoma of bone have questioned the utility of BMAB in the initial staging of patients, but no studies of which we are aware have evaluated the role of BMAB in extraskeletal Ewing sarcoma. We suspected that BMAB was of low diagnostic yield in patients with extraskeletal Ewing sarcoma and exposed patients to potential morbidity without an impact on their clinical course. Question/purpose: Is BMAB a useful test in the staging of extraskeletal Ewing sarcoma? Methods: Between January 1996 and December 2021, our institution evaluated 109 patients with a listed diagnosis of extraskeletal Ewing sarcoma. Those patients were retrospectively reviewed for this study. Of those, we considered patients with biopsy-confirmed diagnosis of extraskeletal Ewing sarcoma. Biopsy was performed based on institutional protocols, with all diagnoses assigned by a board-certified pathologist. Based on that criteria, 96% (105 of 109) were eligible. An additional 18% (20 of 109) were excluded because records of their initial diagnostic and staging workup were not available. This left 78% (85 of 109) for analysis. Of those, 52% (44 of 85) were male. The average age was 32 ± 16 years. Primary tumor locations included extremities in 26% (22 of 85), paraspinal in 20% (17 of 85), chest in 19% (16 of 85), retroperitoneum in 13% (11 of 85), intraabdominal in 12% (10 of 85), intrapelvic in 7% (6 of 85), and head or neck in 4% (3 of 85). Initial diagnostic and staging information, including the use of PET-CT, bone scan, CT chest, and BMAB, was collected. Metastatic disease at the time of presentation or during follow-up was noted. The utility of BMAB was determined by the rate of positive tests in those undergoing BMAB during the initial staging process. Descriptive statistical analysis was sufficient to address the study question, and therefore no comparative statistics were performed. Results: BMAB was obtained during the initial staging process in 64% (54 of 85) of patients. This BMAB was negative in all 54 patients, including those with known metastatic disease. Conclusion: Diagnosing metastatic disease in extraskeletal Ewing sarcoma is important as the presence of metastases at diagnosis adversely affects prognosis. The routine use of BMAB in the staging process of extraskeletal Ewing sarcoma is of low diagnostic yield. BMAB is unlikely to diagnose metastatic involvement even in patients with known metastases to bone. We do not have enough data to suggest whether other modalities, such as PET-CT, might be more useful. Similar studies should be pursued to determine the utility of the remainder of staging modalities in patients with extraskeletal Ewing sarcoma to elucidate the most efficient and effective staging protocol. Level of Evidence: Level III, diagnostic study